Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

全面介紹

書目詳細資料

Principais autores:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2017-06-01
叢編:	Blood Advances
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!